The Value of Sarcopenia, American Society of Anesthesiologists Physical Status Classificatıon and Surgical Outcome Risk Tool in Predicting Postoperative Long-Term Mortality and Morbidity

Background Clinicians face a significant challenge in dealing with mortality after cancer surgery. Various indices have been developed to predict this condition preoperatively. The validity of these indices has also been demonstrated in gastrointestinal tumors. The purpose of this study was to examine the 1-year long-term benefit and superiority of Sarcopenia, American Society of Anesthesiologists Physical Status Classification(ASA-PS) and the Surgical Outcome Risk Tool(SORT) in gastrointestinal system (GI) tumors. Methods A total of 106 patients who had surgery for gastrointestinal tumors were evaluated. To evaluate Sarcopenia, we measured physical performance, muscle strength, and muscle mass. After noting the patients’ ASA-PS values, we used sortsurgery.com to calculate the SORT value. Then, we compared the patients’ 1-year morbidity and mortality after classifying them based on the indices that were examined. Statistical analyses were performed using IBM SPSS version 20 (Chicago, IL, USA). Shapiro–Wilk test, Mann Whitney U test, Chi-Square test, and Fisher’s Exact test were used for statistical analysis. Results Sarcopenia was detected in 12.3% of patients, dynapenia in 51%, and presarcopenia in 7.5%. The mean SORT was 1.56 ± 2.16. The ASA 4 risk group was 3.8%. Complications occurred in 13.2% of patients. Mortality was detected in 15.1% of patients. We found no statistical significance between Sarcopenia, ASA, and SORT in terms of the length of hospital stay, complications, or mortality. Conclusions For patients having major GI tumor surgery, Sarcopenia, ASA-PS, and SORT are not better than one another in predicting 1-year morbidity and mortality.